Issue |
E3S Web Conf.
Volume 319, 2021
International Congress on Health Vigilance (VIGISAN 2021)
|
|
---|---|---|
Article Number | 01012 | |
Number of page(s) | 5 | |
DOI | https://doi.org/10.1051/e3sconf/202131901012 | |
Published online | 09 November 2021 |
Pharmacovigilance in Covid-19 vaccines
1 Hospital of specialties Tangiers, Morocco.
2 Laboratory of Genetic and Biometry, Faculty of Sciences, Ibn Tofail University, Kenitra, Morocco.
3 Laboratory of Botany, Biotechnologies and plants Protection, Faculty of Sciences, Ibn Tofail University, Kenitra, Morocco.
4 Antipoison and Pharmacovigilance Center, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
* Corresponding author: hananebahouq@yahoo.fr
The ongoing pandemic coronavirus disease of 2019 (COVID-19), originated from Wuhan, China, has caused universal challenging and threatening with considerable health impact and economic losses. Therefore, vaccination, as preventive and protective medical countermeasure, remains an excellent issue for reducing morbidity and mortality of this emerging infectious disease. As of April 2021 and by Emergency Use Authorization (EUA) process, 16 vaccines were authorized by at least one national regulatory authority for public use: two Ribonucleic Acid (RNA) vaccines (Pfizer–BioNTech and Moderna), seven conventional inactivated vaccines (BBIBP-CorV manufactured by Siinopharm, CoronaVac, Covaxin, WIBP-CorV, CoviVac, Minhai-Kangtai and QazVac), five viral vector vaccines (Sputnik Light, Sputnik V, Oxford–AstraZeneca, Convidecia, and Johnson & Johnson) and two protein subunit vaccines (EpiVacCorona and RBD-Dimer). As other countries, Morocco has established an anti-COVID-19 vaccine strategy in order to effectively contribute to the monitoring of vaccine safety supported by the national platform health vigilance and regulated by the National Anti-Poison and Pharmacovigilance Center (CAPM). In this review, we recorded the main current developed COVID-19 vaccines and discussed pharmacovigilance strategies and tools related safety and tolerability of those therapies. In parallel, a review of the Moroccan experience in this field is also conducted.
© The Authors, published by EDP Sciences, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.